KR20230013077A - 코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제 - Google Patents

코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제 Download PDF

Info

Publication number
KR20230013077A
KR20230013077A KR1020227044294A KR20227044294A KR20230013077A KR 20230013077 A KR20230013077 A KR 20230013077A KR 1020227044294 A KR1020227044294 A KR 1020227044294A KR 20227044294 A KR20227044294 A KR 20227044294A KR 20230013077 A KR20230013077 A KR 20230013077A
Authority
KR
South Korea
Prior art keywords
cov
sars
mek inhibitor
atr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227044294A
Other languages
English (en)
Korean (ko)
Inventor
슈테판 루드비히
올리버 플란츠
헬렌 엘리자 호프만
율리아 코흐-하이어
미카엘 쉰들러
Original Assignee
아트리바 테라퓨틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트리바 테라퓨틱스 게엠베하 filed Critical 아트리바 테라퓨틱스 게엠베하
Publication of KR20230013077A publication Critical patent/KR20230013077A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227044294A 2020-05-20 2021-05-20 코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제 Pending KR20230013077A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20175739.0A EP3912623B1 (en) 2020-05-20 2020-05-20 Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
EP20175739.0 2020-05-20
PCT/EP2021/063485 WO2021234097A1 (en) 2020-05-20 2021-05-20 Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm

Publications (1)

Publication Number Publication Date
KR20230013077A true KR20230013077A (ko) 2023-01-26

Family

ID=70802645

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044294A Pending KR20230013077A (ko) 2020-05-20 2021-05-20 코로나바이러스 감염 및/또는 covid-19 사이토카인 폭풍의 치료 또는 예방을 위한 mek 억제제

Country Status (11)

Country Link
US (1) US20230241014A1 (cg-RX-API-DMAC7.html)
EP (2) EP3912623B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023526836A (cg-RX-API-DMAC7.html)
KR (1) KR20230013077A (cg-RX-API-DMAC7.html)
CN (1) CN116635022A (cg-RX-API-DMAC7.html)
AU (1) AU2021277517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023013A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178137A1 (cg-RX-API-DMAC7.html)
ES (1) ES2995196T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022014561A (cg-RX-API-DMAC7.html)
WO (1) WO2021234097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3697405T1 (sl) 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
WO2023084489A1 (en) * 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
WO2024073077A1 (en) * 2022-09-30 2024-04-04 60 Degrees Pharmaceuticals Llc Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine
CN116270588B (zh) * 2022-12-26 2025-07-25 中国科学技术大学 Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN117562890B (zh) * 2023-08-03 2026-05-19 中国医学科学院医药生物技术研究所 一种色酮类化合物在制备抗冠状病毒药物中的用途
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002249261A1 (en) * 2001-03-06 2002-09-19 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
SI3697405T1 (sl) * 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections

Also Published As

Publication number Publication date
EP3912623A1 (en) 2021-11-24
AU2021277517A1 (en) 2022-12-08
EP3912623B1 (en) 2024-07-31
CA3178137A1 (en) 2021-11-25
CN116635022A (zh) 2023-08-22
JP2023526836A (ja) 2023-06-23
EP4153159A1 (en) 2023-03-29
EP3912623C0 (en) 2024-07-31
ES2995196T3 (en) 2025-02-07
MX2022014561A (es) 2022-12-15
WO2021234097A1 (en) 2021-11-25
BR112022023013A2 (pt) 2022-12-20
US20230241014A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
JP2023526836A (ja) コロナウイルス感染症および/またはcovid-19サイトカインストームの処置または予防のためのmek阻害剤
Severa et al. Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
Kumar et al. Inflammasome adaptor protein Apoptosis-associated speck-like protein containing CARD (ASC) is critical for the immune response and survival in west Nile virus encephalitis
Kelley et al. Cellular senescence: friend or foe to respiratory viral infections?
US20170027975A1 (en) Methods of Treating Coronavirus Infection
Qin et al. Baicalin induces a potent innate immune response to inhibit respiratory syncytial virus replication via regulating viral non-structural 1 and matrix RNA
De-Simone et al. IFN-gamma inhibits JC virus replication in glial cells by suppressing T-antigen expression
Yuan et al. Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters
Lu et al. HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration
Bello-Perez et al. MERS-CoV ORF4b is a virulence factor involved in the inflammatory pathology induced in the lungs of mice
Marim et al. Inhibition of tryptophan catabolism is associated with neuroprotection during zika virus infection
Wang et al. Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infection in vitro
Du et al. Alisol B 23-acetate broadly inhibits coronavirus through blocking virus entry and suppresses proinflammatory T cells responses for the treatment of COVID-19
Al Dhamen et al. COVID-19: an update on pathogenesis and treatment
Labbé et al. Safety and efficacy of inhaled IBIO123 for severe COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial
Long et al. Phosphoprotein gene of wild-type rabies virus plays a role in limiting viral pathogenicity and lowering the enhancement of BBB permeability
EP4186500A1 (en) Mek inhibitors for the prevention and treatment of long covid syndrome
EA051538B1 (ru) Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19
Kumar et al. Mucosal implications of oral Jak3-targeted drugs in COVID patients
Belouzard et al. Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
Kerr et al. IFN-γ signaling is required for the efficient replication of murine hepatitis virus (MHV) strain JHM in the brains of infected mice
Guayasamin et al. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector
Baek et al. Parental Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Predominates Over Coinfected SARS‐CoV‐2 Delta, Producing Less Lethal Variants in a Long‐Term Replication Mouse Model
US20220323402A1 (en) Treatment, amelioration or prevention of a viral infection
KR102602043B1 (ko) 프랄라트렉세이트(Pralatrexate)를 유효성분으로 포함하는 항바이러스 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902